ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

ClinicalTrials.gov ID: NCT04530110

Public ClinicalTrials.gov record NCT04530110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

Study identification

NCT ID
NCT04530110
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Enrollment
506 participants

Conditions and interventions

Conditions

Interventions

  • Fremanezumab Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 15, 2020
Primary completion
Aug 14, 2025
Completion
Dec 21, 2025
Last update posted
Feb 12, 2026

2020 – 2025

United States locations

U.S. sites
32
U.S. states
23
U.S. cities
30
Facility City State ZIP Site status
Teva Investigational Site 14319 Aurora Colorado 80045
Teva Investigational Site 14368 Colorado Springs Colorado 80907
Teva Investigational Site 14244 Jacksonville Florida 32256
Teva Investigational Site 14325 Miami Florida 33155
Teva Investigational Site 14250 West Palm Beach Florida 33407
Teva Investigational Site 14255 West Palm Beach Florida 33409
Teva Investigational Site 14243 Atlanta Georgia 30328
Teva Investigational Site 14258 Savannah Georgia 31406
Teva Investigational Site 14263 Hoffman Estates Illinois 60169
Teva Investigational Site 14245 Wichita Kansas 67206
Teva Investigational Site 14327 Louisville Kentucky 40202
Teva Investigational Site 14360 Covington Louisiana 70433
Teva Investigational Site 14365 Baltimore Maryland 21201
Teva Investigational Site 14246 Waltham Massachusetts 02451
Teva Investigational Site 14251 Ann Arbor Michigan 48104
Teva Investigational Site 14270 Minneapolis Minnesota 55402
Teva Investigational Site 14376 Ridgeland Mississippi 39157
Teva Investigational Site 14256 Bridgeton Missouri 63044-2513
Teva Investigational Site 14371 New Brunswick New Jersey 08901
Teva Investigational Site 14276 Amherst New York 14226
Teva Investigational Site 14377 Durham North Carolina 27710
Teva Investigational Site 14248 Raleigh North Carolina 27607
Teva Investigational Site 14264 Cincinnati Ohio 45229-3039
Teva Investigational Site 14257 Oklahoma City Oklahoma 73112
Teva Investigational Site 14363 Tulsa Oklahoma 74136
Teva Investigational Site 14364 Philadelphia Pennsylvania 19104-4318
Teva Investigational Site 14374 Bristol Tennessee 37620
Teva Investigational Site 14252 Austin Texas 78731
Teva Investigational Site 14273 Austin Texas 78759
Teva Investigational Site 14367 Dallas Texas 75235-7701
Teva Investigational Site 14375 Salt Lake City Utah 84109
Teva Investigational Site 14323 Norfolk Virginia 23510

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04530110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04530110 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →